Independent analysis puts a SGN liraglutide lot at 95.7%, against 93.4% on the certificate
The supplier has not disputed the finding. It has not explained the gap either.
TheCompound Journal
Reporting on incretins, compounding & the peptide supply chain
Page 40 of 48 of this archive, newest first.
The supplier has not disputed the finding. It has not explained the gap either.
The route did not close because of a rule about peptides.
Follow the resin, not the catalogue.
What the Journal asks when a document arrives unsigned, and what the answers have been.
Follow the resin, not the catalogue.
Follow the resin, not the catalogue.
Follow the resin, not the catalogue.
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
The route did not close because of a rule about peptides.
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
What a laboratory can and cannot know about the provenance, storage history and representativeness of what lands on its bench.
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
The condition on arrival is recorded by some services and not others, and it is one of the more informative lines in a report.
The route did not close because of a rule about peptides.
Follow the resin, not the catalogue.
The Journal submitted the sample and paid for the analysis. The vendor was told in advance.
Nothing on this page is difficult. It is simply unfamiliar, and unfamiliarity is what makes a weak certificate look like a strong one.
A reminder that a purity figure is the output of a method, and that methods differ.
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
The supplier has not disputed the finding. It has not explained the gap either.